The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice

被引:60
作者
Kovacs-Nolan, J. [1 ]
Latimer, L. [1 ]
Landi, A. [1 ]
Jenssen, H. [2 ]
Hancock, R. E. W. [2 ]
Babiuk, L. A. [3 ]
Littel-van den Hurk, S. van Drunen [1 ]
机构
[1] Univ Saskatchewan, Vaccine & Infect Dis Org, Saskatoon, SK S7N 5E3, Canada
[2] Univ British Columbia, Ctr Microbial Dis & Immun Res, Vancouver, BC V6T 1Z4, Canada
[3] Univ Alberta, Edmonton, AB T6G 2J9, Canada
基金
加拿大自然科学与工程研究理事会; 加拿大健康研究院;
关键词
Adjuvant; CpG CON; Host defense peptide; Polyphosphazene; Immune responses; ANTIMICROBIAL-PEPTIDE; DENDRITIC CELLS; VACCINE ADJUVANTS; INTERFERON-GAMMA; B-LYMPHOCYTES; BACTERIAL-DNA; ANTIGENS; OLIGONUCLEOTIDES; DELIVERY; LL-37;
D O I
10.1016/j.vaccine.2009.01.118
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The need to enhance the immunogenicity of purified subunit antigens and modulate resulting immune responses has prompted the development of new adjuvants. Here, the ability of CpG oligodeoxynucleotides (ODN), a bovine host defence peptide indolicidin, and polyphosphazene to synergistically combine and enhance innate and adaptive immune responses was examined in mice. In vitro, the adjuvant combination of CpG ODN, indolicidin and polyphosphazene (CpG/indol/PP) enhanced the secretion of TNF-alpha, IL-12p40, and IL-6 by bone marrow-derived DCs (BMDCs) when compared to the individual components. When co-formulated with ovalbumin (OVA), CpG/indol/PP formed antigen-adjuvant complexes, and enhanced antibody and cell-mediated responses in mice, via both MHC I and II pathways, promoting a more balanced antibody-mediated and type 1-biased cell-mediated immune response. Furthermore, substitution of the proline residues of indolicidin with arginine increased the synergistic adjuvant effect of the peptide, and induced significantly higher IgG1 and IgG2a titers and IFN-gamma secretion, as well as increased uptake by antigen presenting cells. These results clearly demonstrate that the use of a combination of CpG ODN, indolicidin, and polyphosphazene as adjuvant can significantly enhance an antigen-specific immune response. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2055 / 2064
页数:10
相关论文
共 59 条
[1]   Polyphosphazene polyelectrolytes: A link between the formation of noncovalent complexes with antigenic proteins and immunostimulating activity [J].
Andrianov, AK ;
Marin, A ;
Roberts, BE .
BIOMACROMOLECULES, 2005, 6 (03) :1375-1379
[2]   Synthesis and biologically relevant properties of polyphosphazene polyacids [J].
Andrianov, AK ;
Svirkin, YY ;
LeGolvan, MP .
BIOMACROMOLECULES, 2004, 5 (05) :1999-2006
[3]   Protein release from polyphosphazene matrices [J].
Andrianov, AK ;
Payne, LG .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 31 (03) :185-196
[4]   Immunogenicity of bovine herpesvirus 1 glycoprotein D in mice: Effect of antigen form on the induction of cellular and humoral immune responses [J].
BacaEstrada, ME ;
Snider, M ;
Tikoo, SK ;
Harland, R ;
Babiuk, LA ;
LittelVandenHurk, SV .
VIRAL IMMUNOLOGY, 1996, 9 (01) :11-22
[5]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[6]   Immunomodulatory activities of small host defense peptides [J].
Bowdish, DME ;
Davidson, DJ ;
Scott, MG ;
Hancock, REW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (05) :1727-1732
[7]   Cationic host defense (antimicrobial) peptides [J].
Brown, KL ;
Hancock, REW .
CURRENT OPINION IN IMMUNOLOGY, 2006, 18 (01) :24-30
[8]  
BURDIN N, 1995, J IMMUNOL, V154, P2533
[9]   Polyphosphates and other phosphorus-containing polymers for drug delivery applications [J].
Chaubal, MV ;
Sen Gupta, A ;
Lopina, ST ;
Bruley, DF .
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2003, 20 (04) :295-315
[10]   Antimicrobial and chemoattractant activity, lipopolysaccharide neutralization, cytotoxicity, and inhibition by serum of analogs of human cathelicidin LL-37 [J].
Ciornei, CD ;
Sigurdardóttir, T ;
Schmidtchen, A ;
Bodelsson, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (07) :2845-2850